Source · Select Committees · Health and Social Care Committee
Recommendation 9
9
Accepted
Paragraph: 34
Swiftly implement O’Shaughnessy review recommendations for clinical trials and patient engagement.
Recommendation
We welcome Lord O’Shaughnessy’s review of commercial clinical trials, which chimed with a lot of the evidence that we heard in this part of our inquiry. The Government’s positive response to the recommendations is encouraging. We especially endorse the following recommendations and will be keeping a watching brief on the Government’s progress in implementing them, which we expect to be swift: a) Recommendations 2, 3 and 4 to address overly slow and bureaucratic clinical trial set-up and approval processes, in particular the goal for a 60-day turnaround for approvals b) Recommendations 14 - 17 to address the absence of conversation about research from interactions between clinicians and patients and increase the profile and awareness of research among disadvantaged or marginalised groups c) Recommendation 27 to develop an action plan outlining how the Government and delivery partners will implement the recommendations of the review.
Government Response Summary
The government accepts the recommendations in principle, noting it has made five headline commitments backed by £121 million to improve commercial clinical trials and will provide an implementation update in the autumn outlining progress and responding in full to the remaining review recommendations.
Paragraph Reference:
34
Government Response
Accepted
HM Government
Accepted
The Government has previously welcomed all recommendations from Lord O’Shaughnessy’s review of commercial clinical trials in principle and will consider delivery of all the recommendations. As an immediate first step, the Government has made five headline commitments, published alongside the review and backed by up to £121 million6. These headline commitments will improve the speed of commercial clinical trials in the UK. In addition, we will take forward the foundational actions that will be adopted as part of the Government and the health system’s on-going work to support commercial clinical trials. An implementation update will be provided in the autumn, which will outline progress against these commitments as well as responding in full to the remaining review recommendations.